{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:45:43Z","timestamp":1773938743441,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010390","name":"Saint Louis University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clgc.2025.102469","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:47:09Z","timestamp":1763632029000},"page":"102469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real World Hospitalizations in US Veterans Treated for Metastatic Prostate Cancer with Combination Therapy"],"prefix":"10.1016","volume":"24","author":[{"given":"Kara","family":"Ingram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7130-6847","authenticated-orcid":false,"given":"Robert","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9399-8214","authenticated-orcid":false,"given":"Jason M.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-2159","authenticated-orcid":false,"given":"Daniel B.","family":"Eaton Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumrah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-5553","authenticated-orcid":false,"given":"Martin W.","family":"Schoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2025.102469_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clgc.2025.102469_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1970","article-title":"Survival in patients with de novo metastatic prostate cancer","volume":"7","author":"Schoen","year":"2024","journal-title":"JAMA Network Open"},{"issue":"8","key":"10.1016\/j.clgc.2025.102469_bib0003","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"James","year":"2015","journal-title":"Eng J Med"},{"issue":"5","key":"10.1016\/j.clgc.2025.102469_bib0004","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lan Oncol"},{"issue":"32","key":"10.1016\/j.clgc.2025.102469_bib0005","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2025.102469_bib0006","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102469_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.9433","article-title":"Treatment patterns and survival among veterans with de novo metastatic hormone-sensitive prostate cancer","volume":"8","author":"Schoen","year":"2025","journal-title":"JAMA Network Open"},{"issue":"10336","key":"10.1016\/j.clgc.2025.102469_bib0008","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clgc.2025.102469_bib0009","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.clgc.2025.102469_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5006","article-title":"Phase 3 AMPLITUDE trial: niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes","volume":"43","author":"Attard","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102469_bib0011","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41391-022-00514-9","article-title":"Real\u2011world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population\u2011based cohort study in Canada","volume":"26","author":"Shayegan","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"36","key":"10.1016\/j.clgc.2025.102469_bib0012","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.2217\/fon-2023-0377","article-title":"Real\u2011world outcomes for first line next\u2011generation hormonal agents in metastatic prostate cancer: a systematic review","volume":"19","author":"Hettle","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2025.102469_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-016-0793-1","article-title":"Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer","volume":"33","author":"Schweizer","year":"2016","journal-title":"Med Oncol"},{"issue":"21","key":"10.1016\/j.clgc.2025.102469_bib0014","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clgc.2025.102469_bib0015","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102469_bib0016","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","article-title":"Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre\u2011existing cardiovascular comorbidities","volume":"77","author":"Lu\u2011Yao","year":"2020","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102469_bib0017","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamaoncol.2019.1011","article-title":"Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open\u2011label phase 2 study","volume":"5","author":"Attard","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102469_bib0018","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.juro.2015.06.106","article-title":"Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies","volume":"194","author":"Crawford","year":"2015","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.clgc.2025.102469_bib0019","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2217\/fon-2018-0940","article-title":"Enzalutamide, an oral androgen receptor inhibitor for treatment of castration\u2011resistant prostate cancer","volume":"15","author":"Sternberg","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2025.102469_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2023.07.006","article-title":"Hospitalizations among veterans treated for metastatic prostate cancer with abiraterone or enzalutamide","volume":"22","author":"Riekhof","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2025.102469_bib0021","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","article-title":"Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases","volume":"26","author":"Schoen","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.clgc.2025.102469_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.40730","article-title":"Abiraterone vs enzalutamide among US veterans with metastatic hormone-sensitive prostate cancer","volume":"8","author":"Leuva","year":"2025","journal-title":"JAMA Network Open"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:24:51Z","timestamp":1773933891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1558767325001697"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102469","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real World Hospitalizations in US Veterans Treated for Metastatic Prostate Cancer with Combination Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102469"}}